Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

TAO Synergies Inc. TAOX NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
34/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

TAO Synergies Inc. (TAOX) is a Biotechnology company in the Healthcare sector, currently trading at $4.52. It has a SharesGrow Score of 32/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Valuation: TAOX trades at a trailing Price-to-Earnings (P/E) of -0.3 (S&P 500 average ~25).

Financials: revenue is $299,061, +0%/yr average growth. Net income is $29M (loss), growing at -81.6%/yr. Net profit margin is -9609.2% (negative). Gross margin is 100% (+0 pp trend).

Balance sheet: total debt is $0 against $22M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 13.99 (strong liquidity). Debt-to-assets is 0%. Total assets: $26M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 46/100 (Partial), Future ?/100 (Fail), Income 10/100 (Fail).

TAOX SharesGrow Score Overview

43/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 46/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — TAOX

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
TAOX: +0%/yr revenue is, -81.6%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet TAOX: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 13.99 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
46/100
TAOX: Gross margin is 100% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 46/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
10/100
TAOX: Net profit margin is -9609.2%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range1.84-11.98
Volume63.29K
Avg Volume (30D)186.44K
Market Cap$14.85M
Beta (1Y)2.04
Share Statistics
IPO Date2025-07-02
Employees4
CEOJoshua N. Silverman
Financial Highlights & Ratios
Revenue (TTM)$299.06K
Gross Profit$299.06K
EBITDA$-9.04M
Net Income$-28.74M
Operating Income$-9.05M
Total Cash$5.5M
Net Debt$-5.5M
Total Assets$25.84M
Price / Sales (P/S)49.67
Analyst Forecast
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS87167T3005

Price Chart

Track all markets on TradingView
TAOX
TAO Synergies Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
1.84 52WK RANGE 11.98

People Also View

RLYB
RLYB
Rallybio Corporation
$8.28
+0.36%
 BOLD
BOLD
Boundless Bio, Inc.
$1.63
+4.49%
 IBIO
IBIO
iBio, Inc.
$2.10
-4.11%
 NXTC
NXTC
NextCure, Inc.
$12.02
-5.87%
 KLTO
KLTO
Klotho Neurosciences, Inc.
$0.38
-7.10%
 PSTV
PSTV
Plus Therapeutics, Inc.
$5.65
+4.05%
 CVKD
CVKD
Cadrenal Therapeutics, Inc. Common Stock
$4.81
+0.42%
 INTS
INTS
Intensity Therapeutics, Inc.
$5.30
-1.12%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message